Sanofi Aventis Essay

1186 words - 5 pages

RATIO ANALYSIS OF SANOFI-AVENTIS PAKISTAN LIMITED:

* Sanofi-aventis Pakistan limited currently scores 50% in the index.
* Sanofi-aventis Pakistan limited is currently ranked equal 12 out of 3564. This is in the top 0.34% of Technology companies ranked in the index.
* Sanofi-aventis Pakistan limited is currently ranked equal 19 out of a total of 35419 included in the InfoGrok Company Index. This is the top 0.05% of all companies.
* User perception of the company stands at 50%. This differs 0% over the score attributed to the company by other scoring factors

59 | 11.50 | 5.05 |
|
Capital Spending - 5 Yr. Growth Rate | 16.79 | 11.17 | 9.71 | 3.53 |
Financial Strength
| Company | Industry | Sector | S&P 500 |
Quick Ratio (MRQ) | | 1.91 | 1.86 | 0.69 |
Current Ratio (MRQ) | | 2.30 | 2.29 | 1.02 |
LT Debt to Equity (MRQ) | | 9.09 | 20.26 | 151.16 |
Total Debt to Equity (MRQ) | | 11.28 | 24.93 | 198.11 |
Interest Coverage (TTM) | -- | 0.18 | 1.72 | 17.31 |
Profitability Ratios
| Company | Industry | Sector | S&P 500 |
Gross Margin (TTM) | 29.41 | 60.42 | 57.12 | 32.95 |
Gross Margin - 5 Yr. Avg. | 27.12 | 60.02 | 58.86 | 30.98 |
|
EBITD Margin (TTM) | 10.45 | -- | -- | -- |
EBITD - 5 Yr. Avg | 9.88 | 24.18 | 21.63 | 19.43 |
|
Operating Margin (TTM) | 8.31 | 24.70 | 18.45 | -- |
Operating Margin - 5 Yr. Avg. | 6.81 | 18.95 | 15.43 | 14.90 |
|
Pre-Tax Margin (TTM) | 6.50 | 24.97 | 18.51 | 15.67 |
Pre-Tax Margin - 5 Yr. Avg. | 4.85 | 20.14 | 16.15 | 14.45 |
|
Net Profit Margin (TTM) | 3.29 | 18.77 | 13.13 | 11.60 |
Net Profit Margin - 5 Yr. Avg. | 2.93 | 14.62 | 11.06 | 10.66 |
|
Effective Tax Rate (TTM) | 49.33 | 24.92 | 23.95 | 21.93 |
Effecitve Tax Rate - 5 Yr. Avg. | 39.53 | 30.18 | 30.36 | 24.95 |
Efficiency
| Company | Industry | Sector | S&P 500 |
Revenue/Employee (TTM) | 8,586,241 | 5,132,749 | 5,473,912 | 731,888 |
Net Income/Employee (TTM) | 282,738 | 557,881 | 667,175 | 89,705 |
|
Receivable Turnover (TTM) | -- | 2.36 | 3.14 | 8.79 |
Inventory Turnover (TTM) | -- | 1.63 | 2.57 | 7.73 |
Asset Turnover (TTM) | -- | 0.36 | 0.43 | 0.58 |
Management Effectiveness
| Company | Industry | Sector | S&P 500 |
Return on Assets (TTM) | -- | 6.03 | 5.85 | 6.35 |
Return on Assets - 5 Yr. Avg. | 5.38 | 9.28 | 8.69 | 5.71 |
|
Return on Investment (TTM) | -- | 7.22 | 7.12 | 8.19 |
Return on Investment - 5 Yr. Avg. | 11.51 | 11.51 | 10.95 | 7.46 |
|
Return on Equity (TTM) | -- | 8.75 | 8.89 | 18.30 |
Return on Equity - 5 Yr. Avg. | 12.53 | 14.92 | 14.23 | 15.03 |
| Stock Data: | Recent Stock Performance: |

Global Cosmeceuticals Market to Grow at a Cagr of 7.28 Percent

811 words - 4 pages , KOSE Corporation, Medicis Pharmaceutical Corp., Physicians Formula Holdings Inc., Revlon Inc., Royal DSM Nv, ROHTO Pharmaceuticals Co. Ltd., Sanofi-Aventis SA, Shiseido Co., and Strivectin Operating Company Inc. Key questions answered in this report: What will the market size be in 2016 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors

Type 1 Diabetes Market: Global Industry Analysis and Forecast to 2020

981 words - 4 pages artificial pancreas and home infusion therapy for diabetes treatment are some of the trend for the growth of the global type 1 diabetes market. Some of the major companies operating in the global type 1 diabetes market are Eli Lilly and Company, Astrazeneca Plc., B.Braun Melsungen AG, Novo Nordisk A/S, Sanofi-Aventis US, LLC, DiaVacs, Inc., XOMA Corp., Biodel, Inc. and Macrogenics, Inc. Request Full TOC: http

Medicine Sector in Bangladesh

1017 words - 5 pages Health Care 28.73 Zimax Antibiotic Square -4.22 Top Five Multinational Pharmaceuticals in Bangladesh Sl. No. Name of The Company Market Size Market Share (%) Growth (%) 1 Novo Nordisk 2,083,257,490 2.05 -5.85 2 Sanofi Aventis 2,032,579,187 2.00 -6.38 3 Glaxosmithkline (GSK) 1,694,068,206 1.67 4.43 4 Novartis 1,373,449,983 1.35 9.16 5 Roche 709,712,519 0.70 8.66 Marketing Strategy of

Strategy and Ratio Analysis of Gsk

1301 words - 6 pages . It has a good business prospect in Bangladesh which reflected in the 2009 market review by the Pharmaceutical Association of Bangladesh. With Sanofi-Aventis (market share 2.97 per cent) ranked the top among the multinational pharmaceutical companies followed by GlaxoSmithKline (2.24 per cent) in 2009. Ratio Analysis of GSK Internal Liquidity Ratio Analyzing the financial statement of GSK of the year 2009 and 2010

Porter's Five Forces

1183 words - 5 pages (Switzerland), Sanofi Aventis (France), Merck and Pfizer (United States). Europe and the United States account roughly 25 and 50 percent, respectively, of the worldwide pharmaceutical sales. The threat of new entrants into the pharmaceutical industry is very low because of the high costs required to enter the industry, which means their profit is high, as Dr. MacDonald mentioned in the class "The higher the threat the lower the profit and vice versa

Investment

1361 words - 6 pages Pfizer, Novartis, Bayer and Roche which maintain a market share of 4-6%, each. With respect to production, there are 49 manufacturing facilities in country of which 14 are foreign owned. Multinationals with manufacturing facilities include Sanofi-Aventis, Baxter, Bayer, GSK, Novartis, Pfizer and Roche, with EastPharma being the latest to enter the market. In 2010, Turkey imported US$4.24bn and exported around US$560mn worth of pharmaceuticals

Training Methods and Their Use

3021 words - 13 pages employees abroad or other institution within the country. They offer both on-the-job and off-the- job at both theoretical and practical training opportunities. The common types of training are: * Orientation Training * Pharmacists – GMP training * Leadership Training * Etiquette * Safety Training * Corporate Culture * SANOFI-AVENTIS BANGLADESH LIMITED Sanofi-Aventis Bangladesh Limited is the entity that has

Financial Statement Analysis

4114 words - 17 pages Pharmaceuticals Ltd. is a renowned company in Bangladesh. It is a flagship company in the pharmaceutical industry which has reached this mountain of success by fighting many potential competitors like BEXIMCO Pharma, INCEPTA, ACME, RENETA, OPSONIN, SK+F, SANOFI-AVENTIS etc. It initially started as a Partnership in 1958. It was incorporated as a Private Ltd. Company in 1964 and converted into Public Limited Company in 1991. Its initial public offering

Teva Pharmaceutical Hbr

2929 words - 12 pages |36,506 |Switzerland | |4 |Sanofi-Aventis |35,642 |France | |5 |AstraZeneca |32,516 |UK/Sweden | |6 |Hoffmann–La Roche |30,336 |Switzerland | |7 |Johnson & Johnson |29,425 |US | |8

Ed; 3 ; Rc

3638 words - 15 pages the industry cost of the proposal, in order to avoid obstacles, embedded in the external market, global challenges, in the face of innovation. Market share Direct Competitor Comparison NVS = Novartis AG PFE = Pfizer Inc. SNY = Sanofi-Aventis Industry = Drug Manufacturers - Major GSK NVS PFE SNY Industry Market Cap: 99.30B 126.11B 133.49B 85.17B 1.79B Employees: 99,913 100,000 111,500

Case Study of Coke

4537 words - 19 pages product lines was 0.7%, functional foods still managed to eke out growth of 4%. Other companies are benefiting from the same trend. Results released on September 23rd by Danone, a French diary and yogurt company, showed that its bestselling yogurts are those with live bacteria that are said to strengthen immunity or ease constipation. Even drugs companies are eyeing this new market. In March the chairman of Sanofi-Aventis, a French drug firm

Sanofi Example Class Essay

925 words - 4 pages established in 1718 and it went through a lot of merges with other companies. It went from SANOFI to Sanofi-Synthélabo to Sanofi-Aventis in 2004 and finally it settled back again to SANOFI in 2011. SANOFI also acquired a lot of companies like Genzyme for rare diseases, Merial for animal health, Zentiva for generics, and Global pharma in the Middle East. SANOFI has 7 growth platforms which are emerging markets (except Europe and the United States

Swot And Pestel Of Sanofi (French)

869 words - 4 pages États-Unis La Food and Drug Administration, est l’organisme qui a le droit d’autoriser la commercialisation de médicament sur le territoire des États-Unis.C’est l’équivalent en France a l’Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), qui à titre d’exemple, retirer du marché le 10 Janvier 2012 : le MEPRONIZINE, EQUANIL 250 mg et l’EQUANIL 400 mg du laboratoire Sanofi Aventis France et le MEPROBAMATE RICHARD 200 mg

Xyz Pharama Essay

5496 words - 22 pages Pfizer GlaxoSmithKline Sanofi-Aventis Johnson & Johnson Merck AstraZeneca Novartis Bristol-Myers Squibb Roche Eli Lilly Wyeth Abbott Laboratories Amgen Takeda Boehringer Ingelheim Schering-Plough Bayer Novo-Nordisk Schering AG Sankyo US UK France US US UK Switzerland US Switzerland US US US US Japan Germany US Germany Denmark Germany Japan 11 Sales ($ billion) 46.13 31.42 29.60 22.13 21.49

Business Decision Making Essay

1078 words - 5 pages Income (Bn USD)/EPS Share of Revenue from Drugs 2.2 /$1.27 36.9% 15 2.2 /$1.10 65.5% US 14.6 1.5 /$0.58 87.8% Roche EU 12.1 2.5 /$3.20 69.4% Merck US 11.7 1.7 /$0.56 93.7% Abbott US 9.5 1.2 /$1.03 69.1% Sanofi-Aventis EU 8.5 2.0 /$0.60 95.5% GlaxoSmithKline UK 7.4 2.0 /$0.80 84.2% AstraZeneca UK 7.4 2.2 /$1.50 100% Eli